Literature DB >> 27745988

Adverse Reactions to Contrast Material: A Canadian Update.

Alexander Morzycki1, Anuj Bhatia2, Kieran J Murphy3.   

Abstract

Imaging techniques frequently employ contrast agents to improve image resolution and enhance pathology detection. These gadolinium- and iodine-based media, although generally considered safe, are associated with a number of adverse effects ranging from mild to severe. Reactions are classified as either anaphylactoid ("anaphylaxis-like") or nonanaphylactoid, depending on a number of elements that will be reviewed. Herein, we have summarized predisposing risk factors for adverse events resulting from the use of contrast, their associated pathophysiological mechanisms as well as known prophylaxis for the antitreatment of high-risk patients. In the unlikely event that a serious adverse reaction does occur, we have provided a comprehensive summary of treatment protocols. Our goal was to thoroughly evaluate the current literature regarding adverse reactions to radiocontrast agents and provide an up to date review for the health care provider.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Contrast reactions; Management; Premedication

Mesh:

Substances:

Year:  2016        PMID: 27745988     DOI: 10.1016/j.carj.2016.05.006

Source DB:  PubMed          Journal:  Can Assoc Radiol J        ISSN: 0846-5371            Impact factor:   2.248


  9 in total

1.  Pharmacovigilance and radiologists: How well do they get along?

Authors:  Ozlem Celik Aydin; Sonay Aydin; Hakki Zafer Guney
Journal:  Br J Radiol       Date:  2020-09-09       Impact factor: 3.039

2.  Radiomics Study for Differentiating Focal Hepatic Lesions Based on Unenhanced CT Images.

Authors:  Xitong Zhao; Pan Liang; Liuliang Yong; Yan Jia; Jianbo Gao
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

Review 3.  [When are contrast agents really needed? : Cross-sectional imaging with computed tomography and magnetic resonance imaging].

Authors:  G Layer
Journal:  Radiologe       Date:  2019-06       Impact factor: 0.635

4.  Can the lower rate of CT- or MRI-related adverse drug reactions to contrast media due to stricter limitations on patients undergoing contrast-enhanced CT or MRI?

Authors:  Takahiro Maeda; Masafumi Oda; Shinji Kito; Tatsurou Tanaka; Nao Wakasugi-Sato; Shinobu Matsumoto-Takeda; Takaaki Joujima; Yuichi Miyamura; Koichi Kiyota; Kensuke Tsutsumi; Yasuhiro Morimoto
Journal:  Dentomaxillofac Radiol       Date:  2019-10-23       Impact factor: 2.419

Review 5.  [Chemical exchange saturation transfer (CEST) : Magnetic resonance imaging in diagnostic oncology].

Authors:  N von Knebel Doeberitz; S Maksimovic; L Loi; D Paech
Journal:  Radiologe       Date:  2021-01       Impact factor: 0.635

6.  Spontaneous cutaneous adverse drug reaction reports-An analysis of a 10-year dataset in Singapore.

Authors:  Si Xian Wong; Mun Yee Tham; Chee Leok Goh; Han Hui Cheong; Sui Yung Chan
Journal:  Pharmacol Res Perspect       Date:  2019-03-13

7.  Fatal contrast medium-induced adverse response to iohexol in carotid artery angioplasty: A case report.

Authors:  Zhiqi Yang; Rong Li; Jinbin Yue; Yaxuan Wei; Xiaoyan Zhang; Rong Yin
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

Review 8.  Assessment of immediate and non-immediate hypersensitivity contrast reactions by skin tests and provocation tests: A review.

Authors:  Rakesh D Bansie; A Faiz Karim; Maurits S van Maaren; Maud Aw Hermans; Paul LA van Daele; Roy Gerth van Wijk; Saskia M Rombach
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

9.  Pharmacologic and non-pharmacologic interventions to prevent hypersensitivity reactions of non-ionic iodinated contrast media: a systematic review protocol.

Authors:  Hiroyasu Umakoshi; Takashi Nihashi; Hironori Shimamoto; Takehiro Yamada; Hiroaki Ishiguchi; Akira Takada; Naoki Hirasawa; Shunichi Ishihara; Yasuo Takehara; Shinji Naganawa; Matthew Davenport; Teruhiko Terasawa
Journal:  BMJ Open       Date:  2020-03-09       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.